{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:51:56Z","timestamp":1778575916558,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01551-7","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:45:11Z","timestamp":1761237911000},"page":"131-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring Two New, Validated Disease-Specific Outcome Measures to Assess Severity of Chronic Hand Eczema: Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE) and Hand Eczema Symptom Diary (HESD)\u2014A Podcast"],"prefix":"10.1007","volume":"16","author":[{"given":"Raj","family":"Chovatiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"4","key":"1551_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00403-024-02818-3","volume":"316","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Agner T, Baranowski K, et al. Validation of the investigator global assessment of chronic hand eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res. 2024;316(4):110.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1551_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-024-01114-2","volume":"14","author":"S Molin","year":"2024","unstructured":"Molin S, Larsen LS, Joensson P, et al. Development and psychometric validation of a patient-reported outcome measure to assess the signs and symptoms of chronic hand eczema: the hand eczema symptom diary (HESD). Dermatol Ther (Heidelb). 2024;14(3):643\u201369.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1551_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357\u201378.","journal-title":"Contact Dermatitis"},{"issue":"6","key":"1551_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/cod.13804","volume":"84","author":"AS Quaade","year":"2021","unstructured":"Quaade AS, Simonsen AB, Halling AS, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population - a systematic review and meta-analysis. Contact Dermat. 2021;84(6):361\u201374.","journal-title":"Contact Dermat"},{"issue":"6","key":"1551_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/bjd\/ljaf020","volume":"192","author":"C Apfelbacher","year":"2025","unstructured":"Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol. 2025;192(6):1047\u201354.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1551_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0536.2009.01669.x","volume":"62","author":"JP Thyssen","year":"2010","unstructured":"Thyssen JP, Johansen JD, Linneberg A, Menne T. The epidemiology of hand eczema in the general population\u2013prevalence and main findings. Contact Dermat. 2010;62(2):75\u201387.","journal-title":"Contact Dermat"},{"issue":"2","key":"1551_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-019-01164-5","volume":"37","author":"L Grant","year":"2020","unstructured":"Grant L, Seiding Larsen L, Burrows K, et al. Development of a conceptual model of chronic hand eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):692\u2013706.","journal-title":"Adv Ther"},{"issue":"1","key":"1551_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/cod.13113","volume":"80","author":"CJ Apfelbacher","year":"2019","unstructured":"Apfelbacher CJ, Ofenloch RF, Weisshaar E, et al. Chronic hand eczema in Germany: 5-year follow-up data from the CARPE registry. Contact Dermatitis. 2019;80(1):45\u201353.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"1551_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/DER.0000000000000598","volume":"31","author":"S Capucci","year":"2020","unstructured":"Capucci S, Hahn-Pedersen J, Vilsb\u00f8ll A, Kragh N. Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis. 2020;31(3):178\u201384.","journal-title":"Dermatitis"},{"issue":"4","key":"1551_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjd.16147","volume":"178","author":"SMD Ruff","year":"2018","unstructured":"Ruff SMD, Engebretsen KA, Zachariae C, et al. The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):879\u201388.","journal-title":"Br J Dermatol"},{"key":"1551_CR11","unstructured":"Anzupgo\u00ae. Prescribing information. LEO Pharma A\/S; 2025. https:\/\/www.leo-pharma.us\/AnzupgoPI. Accessed 8 Aug 2025."},{"key":"1551_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004055.pub2","author":"WA Christoffers","year":"2019","unstructured":"Christoffers WA, Coenraads P-J, Svensson \u00c5, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD004055.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1551_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332.","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl 1","key":"1551_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jdv.16062","volume":"34","author":"P Elsner","year":"2020","unstructured":"Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):13\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1551_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/12034754231188325","volume":"27","author":"JSS Ho","year":"2023","unstructured":"Ho JSS, Molin S. A review of existing and new treatments for the management of hand eczema. J Cutan Med Surg. 2023;27(5):493\u2013503.","journal-title":"J Cutan Med Surg"},{"key":"1551_CR16","unstructured":"Anzupgo\u00ae. Summary of product characteristics. LEO Pharma A\/S; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/anzupgo-epar-product-information_en.pdf. Accessed 21 Apr 2025."},{"key":"1551_CR17","unstructured":"Anzupgo\u00ae. Summary of product characteristics. LEO Pharma A\/S; 2024. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/9b36e1064f3c6f825f0ffd292f55ccaa49a71992. Accessed 8 Aug 2025."},{"issue":"10451","key":"1551_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA\u00a01and DELTA\u00a02): results from multicentre, randomised, controlled, double-blind, phase\u00a03 trials. Lancet. 2024;404(10451):461\u201373.","journal-title":"Lancet"},{"issue":"4","key":"1551_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","volume":"158","author":"T Ruzicka","year":"2008","unstructured":"Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808\u201317.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1551_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/dth.12362","volume":"29","author":"K Politiek","year":"2016","unstructured":"Politiek K, Christoffers WA, Coenraads PJ, Schuttelaar MA. Alitretinoin and acitretin in severe chronic hand eczema; results from a retrospective daily practice study. Dermatol Ther. 2016;29(5):364\u201371.","journal-title":"Dermatol Ther"},{"issue":"10490","key":"1551_CR21","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/S0140-6736(25)00001-7","volume":"405","author":"AM Gimenez-Arnau","year":"2025","unstructured":"Gimenez-Arnau AM, Pinter A, Sondermann W, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase\u00a03 trial. Lancet. 2025;405(10490):1676\u201388.","journal-title":"Lancet"},{"issue":"2","key":"1551_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2133.2004.06305.x","volume":"152","author":"E Held","year":"2005","unstructured":"Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. a study of inter- and intraobserver reliability. Br J Dermatol. 2005;152(2):302\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1551_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/cod.14699","volume":"92","author":"YT Yuksel","year":"2025","unstructured":"Yuksel YT, Thoning H, Larsen LS, et al. Evaluation of validity, reliability and ability to detect change for the Hand Eczema Severity Index (HECSI) and evaluation of HECSI-75 and HECSI-90 as within-patient responder definitions. Contact Dermatitis. 2025;92(1):51\u201360.","journal-title":"Contact Dermatitis"},{"issue":"11","key":"1551_CR24","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1111\/jdv.19329","volume":"37","author":"AK Janstrup","year":"2023","unstructured":"Janstrup AK, Norreslet LB, Toft-Hansen JM, Ofenloch R, Agner T, Yuksel YT. Assessment of hand eczema severity by patients using the hand eczema severity index (HECSI). J Eur Acad Dermatol Venereol. 2023;37(11):2349\u201354.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1551_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2133.2004.06270.x","volume":"152","author":"PJ Coenraads","year":"2005","unstructured":"Coenraads PJ, Van Der Walle H, Thestrup-Pedersen K, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol. 2005;152(2):296\u2013301.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1551_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40271-019-00373-y","volume":"12","author":"A Barrett","year":"2019","unstructured":"Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445\u201359.","journal-title":"Patient"},{"key":"1551_CR27","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5383","volume":"103","author":"P Bentz","year":"2023","unstructured":"Bentz P, Apfelbacher C, Akst W, et al. Self-reported versus physician-reported severity of chronic hand eczema: concordance analysis based on data from the German chronic hand eczema patient long-term management registry. Acta Derm Venereol. 2023;103:adv00884.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1551_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/jdv.18923","volume":"37","author":"H Ronsch","year":"2023","unstructured":"Ronsch H, Schiffers F, Ofenloch R, et al. Which outcomes should be measured in hand eczema trials? results from patient interviews and an expert survey. J Eur Acad Dermatol Venereol. 2023;37(6):1199\u2013206.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1551_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cod.13212","volume":"80","author":"H Ronsch","year":"2019","unstructured":"Ronsch H, Apfelbacher C, Brans R, et al. Which outcomes have been measured in hand eczema trials? a systematic review. Contact Dermat. 2019;80(4):201\u20137.","journal-title":"Contact Dermat"},{"issue":"12","key":"1551_CR30","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1111\/jdv.16429","volume":"34","author":"H Ronsch","year":"2020","unstructured":"Ronsch H, Apfelbacher C, Brans R, et al. Protocol for the development of a core domain set for hand eczema trials. J Eur Acad Dermatol Venereol. 2020;34(12):2871\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1551_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cod.14303","volume":"89","author":"A Bauer","year":"2023","unstructured":"Bauer A, Thyssen JP, Buhl T, et al. Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: results from the hand eczema symptom diary in a phase\u00a0IIb randomized clinical trial. Contact Dermat. 2023;89(1):46\u201353.","journal-title":"Contact Dermat"},{"issue":"4","key":"1551_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1551_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00403-021-02185-3","volume":"313","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI. Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis. Arch Dermatol Res. 2021;313(10):855\u201361.","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01551-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:21Z","timestamp":1770190821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01551-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01551-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Raj Chovatiya has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics Inc., Argenx, Astria Therapeutics Inc., Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GSK, Incyte, Johnson & Johnson, Kenvue, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, and Zai Lab. Raj Chovatiya is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Benjamin Ehst has received fees\/honoraria\/royalties as an advisory board member, contributor and\/or consultant for AbbVie, AnaptysBio, Arcutis Biotherapeutics, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Evommune, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Proivant, Up-To-Date and UCB; received speaking fees from AbbVie, Dermavant Sciences, Eli Lilly, Incyte, LEO Pharma, Novartis, National Psoriasis Foundation, Regeneron, Ortho Dermatologics, Sanofi-Genzyme and UCB; received institutional funding as an investigator for AbbVie, Aclaris Therapeutics, Allakos, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, BMS, Celgene, Concert Pharmaceuticals, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Incyte, Janssen Biotech, Kymab, LEO Pharma A\/S, Novan Inc., Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, Takeda, UCB, and Ventyx Biosciences. Jonathan Silverberg reports honoraria as a consultant\/advisory board member from LEO Pharma and has acted as a consultant for and\/or received grants\/honoraria from AbbVie, AnaptysBio, Asana Biosciences, Galderma Research and Development, GSK, Glenmark, Kiniksa, LEO Pharma, Lilly, MedImmune, Menlo Therapeutics, Pfizer, PuriCore, Regeneron, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}